Table IV.
Risks and Benefits of Clinical CGES in Pediatric Oncology
| All (N=52) | Role
|
P |
Somatic Confidencea
|
Germline Confidenceb
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fellow (n=22) | Physician (n=30) | Non-confident (n=29) | Confident (n=23) | P | Non-confident (n=31) | Confident (n=21) | P | |||
| What do you perceive as potential risk for your patients and their families by participating in this study? Check all that apply. | ||||||||||
|
| ||||||||||
| Psychological impact | 38 (73) | 14 (64) | 24 (80) | NS# | 21 (72) | 17 (74) | NS# | 22 (71) | 16 (76) | NS# |
| Loss of insurability | 24 (46) | 8 (36) | 16 (53) | NS# | 13 (45) | 11 (48) | NS# | 13 (42) | 11 (52) | NS# |
| Privacy or Confidentiality impact | 18 (35) | 5 (23) | 13 (43) | NS# | 12 (41) | 6 (26) | NS# | 13 (42) | 5 (24) | NS# |
|
| ||||||||||
| What do you perceive as potential benefits for your patients and families by participating in this study? Check all that apply. | ||||||||||
|
| ||||||||||
| Identification of the cause for the patient’s cancer | 31 (60) | 12 (55) | 19 (63) | NS# | 16 (55) | 15 (65) | NS# | 16 (52) | 15 (71) | NS# |
| Help detailing the cancer risk in the family. | 36 (69) | 13 (59) | 23 (77) | NS# | 20 (69) | 16 (70) | NS# | 20 (65) | 16 (76) | NS# |
| Facilitating surveillance and early treatment for second cancers in the patient. | 39 (75) | 16 (73) | 23 (77) | NS# | 21 (72) | 17 (81) | NS# | 22 (71) | 17 (81) | NS# |
| Facilitating surveillance and early treatment for cancer in family members. | 39 (75) | 16 (73) | 23 (77) | NS# | 22 (76) | 17 (74) | NS# | 22 (71) | 17 (81) | NS# |
Data presented as frequency (percent).
a
Defined as confidence in knowledge of interpreting results of somatic genomic findings.
b
Defined as confidence in knowledge of interpreting results of germline genomic findings.
NS# = Not statistically significant